Healthcare Sales & Marketing Network News: Hemorrhage

Searching News Database: Hemorrhage

HSMN NewsFeed - 13 Apr 2026
Lilly's Jaypirca (Pirtobrutinib) Significantly Extended Progression-Free Survival When Added to a Venetoclax Time-Limited Regimen in Patients with Previously Treated CLL/SLL
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Feb 2026
Vesalio Expands International Neurovascular Portfolio with CE Mark of NeVa VS and NeVa 3.0 mm and Receives Additional FDA 510(k) Clearance for its Aspiration Catheters
Devices Neurology Interventional Regulatory

HSMN NewsFeed - 15 Jan 2026
BD Receives FDA 510(k) Clearance for EnCor EnCompass(TM) Breast Biopsy and Tissue Removal System
Devices FDA

HSMN NewsFeed - 7 Nov 2025
Laborie Announces Agreement to Acquire the JADA(R) System from Organon
Devices Acquisitions

HSMN NewsFeed - 27 Oct 2025
Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 12 Aug 2025
U.S. Military Study Identifies TITAN CSR(R) Retractor as Top Surgical Retractor for Deployed Trauma Care
Devices Surgery

HSMN NewsFeed - 5 Aug 2025
Instylla Appoints MedTech Leader Sean Boyle as Chief Executive Officer
Devices Interventional Personnel

HSMN NewsFeed - 13 Jan 2025
Cresilon Announces U.S. Nationwide Launch of TRAUMAGEL
Devices FDA

HSMN NewsFeed - 30 Dec 2024
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig(TM) with ENHANZE(R) for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo(R) (nivolumab) Indications
Biopharmaceuticals Drug Delivery Oncology FDA

HSMN NewsFeed - 14 Nov 2024
Stryker Launches Next Generation of SurgiCount+ to Help Improve the Standard of Care in Hospitals for Sponge Management and Blood Loss Assessment
Devices Surgery Product Launch

HSMN NewsFeed - 20 Sep 2024
Stryker Completes Acquisition of NICO Corporation, Expanding Minimally Invasive Solutions for Brain Tumor Removal and Stroke Care
Devices Neurosurgery Mergers & Acquisitions

HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jun 2024
Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients
Biopharmaceuticals Neurology

HSMN NewsFeed - 3 May 2024
Leading Academic Neurosurgeons Describe New NICO Myriad SPECTRA(TM) System as a 'Game-Changing Advancement' in Surgical Removal of High-Grade Glioma Brain Tumors
Devices Neurosurgery Oncology

HSMN NewsFeed - 22 Nov 2022
U.S. Food and Drug Administration Approves CSL's Hemgenix(R) eEtranacogene dezaparvovec-drlb), the First Gene Therapy for Hemophilia B
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 23 Aug 2022
IRRAS Announces First Patient Treatments at Mount Sinai Health System in New York as Part of the DIVE Study
Devices Neurosurgery Monitoring

HSMN NewsFeed - 15 Aug 2022
Boston Scientific Announces Acquisition of Obsidio, Inc.
Devices Interventional Mergers & Acquisitions

HSMN NewsFeed - 9 Aug 2022
CereVasc Announces FDA Approval of Second IDE Study of the eShunt(R) System
Devices Neurosurgery Interventional FDA

HSMN NewsFeed - 6 Jul 2022
ClearMind Biomedical Clears FIM Clinical Trial for Least Invasive ICH Treatment to Date
Devices Neurosurgery

HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Feb 2022
FDA Approves JUVÉDERM(R) VOLBELLA(R) XC for Undereye Hollows
Devices Dermatology FDA

HSMN NewsFeed - 13 Jan 2022
PANTHERx Rare(R) Selected by Xeris Pharmaceuticals to Distribute Recorlev(R) (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients with Cushing's Syndrome
Biopharmaceuticals Distribution

HSMN NewsFeed - 9 Jul 2021
Single Pass Closes Seed Funding Round
Devices Surgery Venture Capital

HSMN NewsFeed - 2 Jun 2021
Prytime Medical Closes Oversubscribed $6M Inside Funding Round to Fuel Commercialization Growth
Devices Venture Capital

HSMN NewsFeed - 28 May 2021
IRRAS Announces publication of a Case report from Buffalo General Medical Center, highlights clinical superiority of IRRAflow treatment versus traditional drainage
Devices Neurosurgery Monitoring

HSMN NewsFeed - 7 May 2021
Perosphere Technologies Announces CE-IVD Marking of the Perosphere Technologies PoC Coagulometer System for DOAC and Heparin Testing
Devices Diagnostics Regulatory

HSMN NewsFeed - 6 Apr 2021
IRRAS Announces Collaboration with Aarhus University Hospital, Scandinavian Leader in Neurosurgery, to Advance Use of IRRAflow
Devices Neurosurgery Monitoring

HSMN NewsFeed - 23 Nov 2020
Rapid Medical Expands Comaneci(TM) CE Mark Indication to Include Vasospasm Treatment
Devices Interventional Neurology Regulatory

HSMN NewsFeed - 16 Nov 2020
Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience
Biopharmaceuticals

HSMN NewsFeed - 22 Oct 2020
IRRAS Announces Key IRRAflow Commercial Milestones in Germany
Devices Neurosurgery Monitoring

HSMN NewsFeed - 11 Aug 2020
IRRAS Announces First Global Patient Treatment with Newly Developed Hummingbird Solo ICP Monitoring System
Devices Neurosurgery Monitoring

HSMN NewsFeed - 31 Jul 2020
CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development
Devices

HSMN NewsFeed - 19 May 2020
ChromaCode Raises $10 Million Series C Financing From Adjuvant Capital
Diagnostics Venture Capital

HSMN NewsFeed - 25 Mar 2020
University of Helsinki, a Global Neurosurgery Leader and IRRAS Will Collaborate to Advance Uses of IRRAflow
Devices Neurosurgery Monitoring

HSMN NewsFeed - 5 Mar 2020
New Data Demonstrates Andexxa(R) Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Biopharmaceuticals

HSMN NewsFeed - 16 Dec 2019
IRRAS Announces US Launch of Hummingbird Products for Neurocritical Care
Devices Neurosurgery Monitoring Product Launch

HSMN NewsFeed - 9 Dec 2019
Sight Sciences Appoints Erica Rogers to its Board of Directors
Devices Ophthalmology Personnel

HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Sep 2019
Allergan Receives FDA Approval of Juvéderm VOLUMA(R) XC For Mid-Face Injection Via Cannula
Biopharmaceuticals Devices Dermatology FDA

HSMN NewsFeed - 13 Aug 2019
FDA Approves EYLEA(R) (aflibercept) Injection Prefilled Syringe
Biopharmaceuticals Drug Delivery Ophthalmology FDA

HSMN NewsFeed - 18 Jun 2019
Breakthrough Device Designation received from the FDA
Devices FDA

HSMN NewsFeed - 17 Apr 2019
Aidoc Raises $27 Million to Expand Its Life-saving Artificial Intelligence Solutions by 700% Across Medical Imaging
Devices Radiology Venture Capital

HSMN NewsFeed - 11 Feb 2019
BioDirection Receives Breakthrough Device Designation from FDA for Tbit(TM) System
Devices Diagnostics Neurology FDA

HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Oct 2018
EYLEA(R) (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 17 Oct 2018
Gauss raises $20 million in Series C from Northwell Health and SoftBank Ventures Korea for AI-Enabled Platform for the Operating Room
Devices Surgery Monitoring Venture Capital

HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Sep 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 28 Aug 2018
Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA(R) (edoxaban) in Patients with Nonvalvular Atrial Fibrillation in Routine Clinical Practice
Biopharmaceuticals

HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Aug 2018
Vyxeos(R) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Aug 2018
ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development
Biopharmaceuticals Neurology

HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Aug 2018
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 8 Aug 2018
A First in the World of Radiology: Aidoc Receives FDA Clearance to Enable Radiologists to Triage Patients Using AI
Devices Radiology FDA

HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jul 2018
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Jun 2018
Sera Prognostics Appoints Dr. Garrett K. Lam as Chief Medical Officer
Diagnostics OB/GYN Personnel

HSMN NewsFeed - 6 Jun 2018
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine(R) (sargramostim) for the Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA

HSMN NewsFeed - 29 May 2018
Egalet Announces Large Regional Plan to Cover SPRIX(R) Nasal Spray
Biopharmaceuticals Reimbursement

HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 May 2018
MaxQ-AI Receives CE Mark Approval for Accipio(TM)Ix Intracranial Hemorrhage Artificial Intelligence Software Platform
Devices Radiology Neurology Regulatory

HSMN NewsFeed - 19 Mar 2018
EYLEA(R) (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 1 Feb 2018
Partner Therapeutics (PTx) Acquires Leukine(R) from Sanofi
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 29 Jan 2018
MedyMatch Receives Expedited Access Pathway / Breakthrough Device Designation from the FDA to Accelerate Market Access for Intracranial Hemorrhage Software
Devices Radiology Neurosurgery FDA

HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jan 2018
New Absorbable Adjunctive Hemostat From Ethicon Helps Surgeons Control Disruptive Bleeding More Efficiently
Devices Surgery Product Launch

HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Oct 2017
Alcyone Lifesciences Receives EU CE Mark Approval for Alivio Ventricular Catheter and Flusher System for Treatment of Hydrocephalus
Devices Neurosurgery Regulatory

HSMN NewsFeed - 1 Sep 2017
FDA approves Mylotarg for treatment of acute myeloid leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Jun 2017
Ethicon Announces FDA Approval For SURGICEL(R) Powder Absorbable Hemostat
Devices Surgery FDA

HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 May 2017
Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Biopharmaceuticals

HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Mar 2017
Revolutionary UroLift(R) System Launches in Ireland
Devices Urology Product Launch

HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Nov 2016
Neural Analytics Announces Commercial Launch of Lucid(TM) M1 Transcranial Doppler Ultrasound System at 9th Annual Society of Vascular and Interventional Neurology Meeting
Devices Monitoring Neurology Product Launch

HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Sep 2016
European Commission Approves CABOMETYX(TM) (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Aug 2016
Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4(TM) Study of Factor Xa Inhibitor Antidote AndexXa(TM) (andexanet alfa) in Patients with Acute Major Bleeding
Biopharmaceuticals

HSMN NewsFeed - 5 Aug 2016
Teva Announces Launch of Generic Gleevec(R) Tablets in the United States
Biopharmaceuticals Generics Oncology Product Launch

HSMN NewsFeed - 29 Jul 2016
Edge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage
Biopharmaceuticals Neurosurgery

HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals

HSMN NewsFeed - 21 Jun 2016
Savara Pharmaceuticals Acquires Serendex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Feb 2016
Z-Medica Receives Expanded CE Mark for QuikClot(R)
Devices Regulatory

HSMN NewsFeed - 24 Nov 2015
Sobi and Biogen’s ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
Biopharmaceuticals Regulatory

HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Oct 2015
Medical Device Firm iTraumaCare Launches Updated Version of iTClamp Hemorrhage Control System
Devices Product Launch

HSMN NewsFeed - 1 Oct 2015
U.S. FDA Approves JUVEDERM(R) ULTRA XC for Use in Lips
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 22 Jul 2015
KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in Diabetic Macular Edema and Hereditary Angioedema
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 8 Apr 2015
Alzheon Announces $10 Million Series A Financing
Biopharmaceuticals Neurology

HSMN NewsFeed - 6 Apr 2015
FDA Expands Indication for EVARREST(R) Fibrin Sealant Patch
Devices Surgery FDA

HSMN NewsFeed - 23 Jan 2015
The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products: KENGREXAL(TM) (cangrelor), ORBACTIV(TM) (oritavancin) and RAPLIXA(TM) (sealant powder)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Aug 2014
Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A
Biopharmaceuticals Regulatory

HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jun 2014
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Jun 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2014
EkoSonic(R) Endovascular System Receives FDA Clearance for the Treatment of Pulmonary Embolism in the USA
Devices Interventional FDA

HSMN NewsFeed - 12 May 2014
FDA Approves ZONTIVITY(TM) (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 24 Apr 2014
Endo Acquires Rights to Sumavel(R) DosePro(R)
Biopharmaceuticals Drug Delivery Acquisitions

HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 4 Apr 2014
Integra LifeSciences Announces Camino(R) Flex Ventricular Catheter Receives FDA Clearance for Use With MRI Scans
Devices Neurosurgery FDA

HSMN NewsFeed - 25 Mar 2014
Exelixis Receives Approval for COMETRIQ(R) (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Mar 2014
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Mar 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Feb 2014
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology

HSMN NewsFeed - 20 Feb 2014
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Feb 2014
Two-Year Results From Phase 3 VISTA Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 5 Feb 2014
Reverse Medical(R) Corporation Announces New Patent for the Micro Vascular Plug (MVP(R))
Devices Interventional

HSMN NewsFeed - 18 Dec 2013
Regeneron Announces FDA Acceptance of EYLEA(R) (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 13 Dec 2013
Neumedicines Presents HemaMax(TM) Clinical Data at the ASH Conference
Biopharmaceuticals

HSMN NewsFeed - 22 Nov 2013
EYLEA(R) (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 18 Nov 2013
Auxilium Announces Results of the XIAFLEX(R) in Dupuytren's MULTICORD Contracture Trial
Biopharmaceuticals

HSMN NewsFeed - 12 Nov 2013
Bayer receives approval for Eylea(R) as new drug to treat wet Age-Related Macular Degeneration Patients in Canada
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 5 Nov 2013
OrSense Receives FDA Clearance for Its Noninvasive Hemoglobin Monitor
Devices Monitoring FDA

HSMN NewsFeed - 22 Oct 2013
Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 18 Oct 2013
ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Oct 2013
Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours (GIST), A Rare Form Of Sarcoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 3 Oct 2013
Medical Device Firm iTraumaCare Selects North American Distributors for iTClamp Hemorrhage Control System
Devices Distribution

HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch

HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology

HSMN NewsFeed - 30 Aug 2013
Bayer's Stivarga(R) (regorafenib) Tablets Approved in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Aug 2013
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Aug 2013
Bard Announces Agreement to Acquire Medafor, Inc.
Devices Surgery Mergers & Acquisitions

HSMN NewsFeed - 31 Jul 2013
Advanced Circulatory Closes $2 Million Bridge Financing
Devices Venture Capital

HSMN NewsFeed - 31 Jul 2013
New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on Findings of Reduced Rate of Stent Thrombosis With BRILINTA (ticagrelor)
Biopharmaceuticals Devices Interventional Cardiology

HSMN NewsFeed - 26 Jul 2013
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 4 Jun 2013
Edge Therapeutics Raises $18 Million to Advance Clinical Development of Potentially Life-Saving Hospital Products
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 28 May 2013
Medical Device Firm iTraumaCare(TM) Receives FDA 510(k) Clearance for iTClamp(TM) Hemorrhage Control System
Devices FDA

HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Apr 2013
Integra LifeSciences Debuts Next-Generation Camino(R) Platform at 2013 American Association of Neurological Surgeons Annual Meeting
Devices Neurosurgery Monitoring Product Launch

HSMN NewsFeed - 21 Mar 2013
Medical Device Firm iTraumaCare Receives European Union CE Marking for iTClamp(TM) Hemorrhage Control System
Devices Regulatory

HSMN NewsFeed - 19 Feb 2013
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 5 Feb 2013
ZALTRAP(R) (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Dec 2012
FDA Approves EVARREST(TM) Fibrin Sealant Patch
Devices Surgery FDA

HSMN NewsFeed - 6 Dec 2012
EYLEA(R) (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 27 Nov 2012
EYLEA(R) (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 7 Nov 2012
URGENT NOTICE -- DRUG RECALL: Boehringer Ingelheim Pharmaceuticals, Inc. Initiates a Voluntary Recall of a Single Manufacturing Lot of Pradaxa(R) (dabigatran etexilate mesylate) Capsules 75mg in the U.S. and Puerto Rico
Biopharmaceuticals Cardiology Product Recall

HSMN NewsFeed - 29 Oct 2012
Bayer's Stivarga(R) (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Oct 2012
Teva Receives Approval For SYNRIBO(TM) (Omacetaxine Mepesuccinate) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Sep 2012
Masimo Announces $1 Million Commitment to Action with the Clinton Global Initiative to Solve Maternal Mortality & Anemia
Devices Monitoring

HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Aug 2012
Edge Therapeutics Appoints Drug-Delivery Luminary Dr. Robert Langer to Chair Scientific Advisory Committee
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Jul 2012
OrSense Introduces Glasswing(TM), its Next-Generation, Wireless, Non-Invasive Hemoglobin Monitoring System for Anemia Screening
Devices Monitoring

HSMN NewsFeed - 6 Jun 2012
HemCon Adds Barry Starkman as CEO
Devices Personnel

HSMN NewsFeed - 26 Apr 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 8 Mar 2012
Regeneron and Bayer Announce Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 18 Nov 2011
EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE(TM) for Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Nov 2011
Avanca’s RPD(R) Safety Syringe Improves Clinical Outcomes and Decreases Patient Pain
Devices

HSMN NewsFeed - 25 Oct 2011
Lilly Announces Withdrawal of Xigris(R) Following Recent Clinical Trial Results
Biopharmaceuticals

HSMN NewsFeed - 26 Aug 2011
Boehringer Ingelheim to Launch RE-ALIGN Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
Biopharmaceuticals Cardiology

HSMN NewsFeed - 13 Jun 2011
Gore Receives Health Canada Approval for GORE(R) SEAMGUARD(R) Bioabsorbable Staple Line Reinforcement
Devices Surgery Regulatory

HSMN NewsFeed - 19 Apr 2011
Sangart Announces Closing of $50 Million Series G Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 25 Mar 2011
Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 25 Feb 2011
FDA Grants Full Approval for PROMACTA(R) (eltrombopag) for Treatment of Rare Blood Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Jan 2011
PhysioSonics Completes Series B Funding
Devices Monitoring Venture Capital Personnel

HSMN NewsFeed - 26 Jan 2011
Bristol-Myers Squibb and sanofi-aventis Announce U.S. FDA Decision to Grant Pediatric Exclusivity For PLAVIX
Biopharmaceuticals Cardiology Generics FDA

HSMN NewsFeed - 18 Jan 2011
Z-Medica Introduces QuikClot Combat Gauze LE Hemostatic Dressing for Law Enforcement and EMS
Devices Wound Care

HSMN NewsFeed - 23 Dec 2010
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Dec 2010
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 14 Dec 2010
Large Canadian Heart Valve Study Provides Evidence of On-X(R) Heart Valve Superior Performance
Devices Cardiology

HSMN NewsFeed - 6 Dec 2010
XIAFLEX(R) Effective in Nonsurgically Treating MP and PIP Joints with Dupuytren's Contractures in Second Pivotal Study
Biopharmaceuticals

HSMN NewsFeed - 15 Nov 2010
Rivaroxaban Significantly Reduces Risk of Stroke in Patients With Atrial Fibrillation With Comparable Safety vs. Warfarin in Pivotal Phase 3 Study
Biopharmaceuticals Cardiology Neurology

HSMN NewsFeed - 2 Nov 2010
Ligand Announces Approval for Revolade(R) in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Oct 2010
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology Neurology FDA

HSMN NewsFeed - 20 Oct 2010
Z-Medica Signs Distribution Agreement with Vingmed AB and Mediplast AB
Devices Distribution

HSMN NewsFeed - 18 Oct 2010
OrSense Continuous Non Invasive Hemoglobin Monitoring System Demonstrates Accurate Performance During Hemorrhage Conditions
Devices Monitoring

HSMN NewsFeed - 14 Oct 2010
Z-Medica Signs Distribution Agreement with Stöpler
Devices Distribution

HSMN NewsFeed - 27 Sep 2010
OrSense Introduces Non-Invasive Hemoglobin System for Anemia Monitoring in Maternal Health
Devices Monitoring

HSMN NewsFeed - 16 Jul 2010
GTC Biotherapeutics Regains US Rights to ATryn(R) ; the First Recombinant Antithrombin Product Approved in the World
Biopharmaceuticals

HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 May 2010
Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Apr 2010
Altheos Completes $20 Million Series A Financing to Develop Next-Generation Glaucoma Treatment
Biopharmaceuticals Ophthalmology Venture Capital

HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jan 2010
Study Published in the American Journal of Ophthalmology Examines Investigational Use of Macugen in Patients With Branch Retinal Vein Occlusion (BRVO)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 29 Jan 2010
Diffusion Pharmaceuticals LLC Closes on $5.9 Million Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 14 Jan 2010
New Published Study Finds Masimo PVI(R) Predicts Fluid Responsiveness as Accurately as Invasive Stroke Volume Variation in Mechanically-Ventilated Patients
Devices Monitoring

HSMN NewsFeed - 11 Jan 2010
Interim Study Data Indicate Improved Blood Pressure Management With Cardene(R) I.V. Compared to Labetalol in Patients with Acute Stoke
Biopharmaceuticals Cardiology Neurology

HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Dec 2009
Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Oct 2009
OrSense's NBM-200MP System for Continuous Non-Invasive Hemoglobin and Blood Oximetry Measurements Achieves Superior Performance in Hospital Setting
Devices Monitoring Surgery

HSMN NewsFeed - 16 Oct 2009
FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Sep 2009
CryoLife Announces First Clinical Use of BioFoam(R)
Devices Surgery

HSMN NewsFeed - 8 Sep 2009
Salix Receives FDA Marketing Approval for METOZOLV ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Aug 2009
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
Biopharmaceuticals Interventional Cardiology

HSMN NewsFeed - 25 Aug 2009
CAS Medical Systems, Inc. Announces FDA 510(k) Clearance Expanding Labeling for FORE-SIGHT Cerebral Oximeter
Devices Monitoring FDA

HSMN NewsFeed - 18 Aug 2009
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Aug 2009
Acetylon Pharmaceuticals Raises $7.25 Million Series A to Develop Next-Generation Selective HDAC Inhibitors for Cancer and Rheumatoid Arthritis
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 4 Aug 2009
CryoLife Receives CE Mark Approval for BioFoam(R) Hemostatic Technology
Devices Surgery Regulatory

HSMN NewsFeed - 3 Aug 2009
FDA Approves Avastin for the Most Common Type of Kidney Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Jul 2009
Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 23 Jul 2009
Allergan Receives FDA Approval for ACUVAIL Ophthalmic Solution for the Treatment of Pain and Inflammation Following Cataract Surgery
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 24 Jun 2009
Medtronic Announces Two Worldwide Clinical Trials to Study Medical Device Interventions for Stroke
Devices Monitoring Cardiology Neurology

HSMN NewsFeed - 18 Jun 2009
Allergan Receives FDA Approval for OZURDEX Biodegradable, Injectable Steroid Implant with Extended Drug Release for Retinal Disease
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 15 Jun 2009
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 1 Jun 2009
Study Concludes PillCam ESO(R) Correlates Well With EGD in Detecting and Grading Esophageal Varices -- A Potentially Lethal Complication of Advanced Liver Disease
Devices Gastroenterology

HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 May 2009
Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
Devices Interventional Neurology

HSMN NewsFeed - 13 May 2009
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
Biopharmaceuticals Cardiology

HSMN NewsFeed - 11 May 2009
Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 May 2009
FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 Mar 2009
Cardium's InnerCool Announces Journal of Neurotrauma Highlights Hypothermia Therapy's Role in Post Cardiac Arrest, and Traumatic Brain and Spinal Cord Injury Patients
Devices Neurosurgery

HSMN NewsFeed - 25 Mar 2009
Top Neurology Programs Control Fever with Arctic Sun Cooling Technology
Devices Neurology

HSMN NewsFeed - 24 Mar 2009
OrSense Receives European CE Mark Approval for Continuous Non-Invasive Hemoglobin and Pulse Oximetry Monitoring System
Devices Monitoring Regulatory

HSMN NewsFeed - 20 Mar 2009
Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
Biopharmaceuticals Cardiology

HSMN NewsFeed - 18 Mar 2009
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Mar 2009
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Biopharmaceuticals Cardiology

HSMN NewsFeed - 11 Mar 2009
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Mar 2009
CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals

HSMN NewsFeed - 17 Jan 2009
CSL Behring Receives FDA Approval of RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Dec 2008
Cardium's InnerCool Awarded U.S. Supplier Agreement With Novation LLC
Devices Group Purchasing

HSMN NewsFeed - 24 Nov 2008
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 23 Nov 2008
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Oct 2008
New Multicenter Study Underscores Value of Using PillCam(R) SB in Children Younger Than 8
Devices Gastroenterology

HSMN NewsFeed - 20 Oct 2008
Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System
Devices FDA

HSMN NewsFeed - 20 Oct 2008
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Sep 2008
New Studies Highlight Benefits of Coblation(R)-Assisted Procedures in Airway Fire Prevention and Endoscopic Sinus Surgery
Devices Surgery

HSMN NewsFeed - 19 Sep 2008
FDA Approves GE Healthcare's AdreView (Iobenguane I 123 Injection) Diagnostic Agent for Detecting Neuroendocrine Tumors in Children, Adults
Biopharmaceuticals Radiology FDA

HSMN NewsFeed - 8 Sep 2008
New Recombinant XYNTHA Now Available for Patients with Hemophilia A
Biopharmaceuticals

HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Sep 2008
Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 2 Sep 2008
New Data Shows Anticlotting Medicine, AGGRASTAT(R), Lowers Incidence of Heart Attack, in Patients Who Respond Poorly to Aspirin or Clopidogrel, after Elective Coronary Angioplasty
Biopharmaceuticals Cardiology

HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Jul 2008
Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
Devices Regulatory

HSMN NewsFeed - 11 Jul 2008
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jun 2008
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2008
New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 May 2008
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Biopharmaceuticals

HSMN NewsFeed - 13 May 2008
Siemens Introduces Dual Energy Applications for General Imaging
Devices Radiology

HSMN NewsFeed - 29 Apr 2008
Cardium Reports on Science Channel Series Featuring InnerCool's Endovascular Cooling During Brain Surgery at Stanford University
Devices Neurosurgery

HSMN NewsFeed - 21 Apr 2008
Genentech Provides Update on ''AVAiL'' Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2008
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 15 Apr 2008
Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
Devices Cardiology

HSMN NewsFeed - 10 Apr 2008
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Apr 2008
Novartis to further strengthen its healthcare portfolio by acquiring 25% stake in Alcon from Nestlé with right to take over majority ownership of the world leader in eye care
Biopharmaceuticals Ophthalmology Mergers & Acquisitions

HSMN NewsFeed - 29 Mar 2008
Angiomax Demonstrated Improved Outcomes in Acute Heart Attack Patients Undergoing Primary Angioplasty Independent of Individual Risk Factors
Biopharmaceuticals Interventional Cardiology

HSMN NewsFeed - 28 Mar 2008
NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
Devices Ophthalmology

HSMN NewsFeed - 27 Mar 2008
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Mar 2008
U.S. Army Study Reports WoundStat(TM) is Most Effective
Devices Wound Care

HSMN NewsFeed - 19 Mar 2008
Cardium's InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
Devices Distribution

HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Mar 2008
Siemens Introduces New Dual Energy Applications to SOMATOM Definition
Devices Radiology

HSMN NewsFeed - 6 Mar 2008
Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
Devices Interventional

HSMN NewsFeed - 23 Feb 2008
FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Feb 2008
Wyeth's XYNTHA Approved by FDA for Treatment of Hemophilia A
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Jan 2008
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Jan 2008
Alsius Corporation Launches Thermogard XP(TM) Intravascular Temperature Management System
Devices

HSMN NewsFeed - 14 Jan 2008
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Biopharmaceuticals

HSMN NewsFeed - 4 Jan 2008
ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke
Biopharmaceuticals Neurology

HSMN NewsFeed - 21 Dec 2007
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 12 Dec 2007
Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
Biopharmaceuticals Neurology Interventional

HSMN NewsFeed - 10 Dec 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Dec 2007
Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
Biopharmaceuticals

HSMN NewsFeed - 9 Dec 2007
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Dec 2007
Genentech Provides Update from Avastin FDA Advisory Meeting
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Nov 2007
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Nov 2007
Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Nov 2007
PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Nov 2007
Actelion: Pivlaz (Clazosentan) Phase III Study Initiated to Demonstrate Prevention of Vasospasm-Related Morbidity and All-Cause Mortality After Aneurysmal Subarachnoid Hemorrhage
Biopharmaceuticals Neurosurgery

HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 6 Nov 2007
Study Finds Starion Instruments' Tissue Welding Technology Reduces Pain and Bleeding in Tonsillectomy Patients
Devices Surgery

HSMN NewsFeed - 2 Nov 2007
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2007
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Biopharmacetuicals

HSMN NewsFeed - 30 Oct 2007
Significant New Data on Roche's PEGASYS(R) and Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
Biopharmaceuticals

HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Oct 2007
InnerCool Licenses New Therapeutic for Potential Use in Stroke Patients
Devices Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 15 Oct 2007
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 27 Sep 2007
FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 24 Sep 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 18 Sep 2007
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Sep 2007
Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Aug 2007
MGI PHARMA Signs Agreement for Rights to Novel Treatment for Thrombocytopenia
Biopharmaceuticals Licensing

HSMN NewsFeed - 24 Aug 2007
Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Aug 2007
Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Aug 2007
Abraxis BioScience Receives FDA Approval for Oxytocin Injection 10 USP Units/mL in a 30 mL Vial
Biopharmaceuticals Distribution

HSMN NewsFeed - 27 Jul 2007
Positive Aggrastat(R) Results Versus Integrilin(R) Featured in American Heart Journal
Biopharmaceuticals Interventional Cardiology

HSMN NewsFeed - 16 Jul 2007
Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jul 2007
Wyeth Begins Marketing and Distributing BeneFIX in Europe
Biopharmaceuticals Distribution

HSMN NewsFeed - 2 Jul 2007
VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Jun 2007
PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 Jun 2007
Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) capsules in Diverse Group of Highly Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 4 Jun 2007
New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 May 2007
FDA Approves Lovenox(R) (Enoxaparin Sodium Injection) for the Most Severe Type of Heart Attack
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 8 May 2007
ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 7 May 2007
Cook Medical's Women's Health Division Experiences Record Growth
Devices

HSMN NewsFeed - 2 May 2007
Barr Receives Approval for Generic Nimotop(R) Capsules, 30 mg
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 2 May 2007
FDA Approves FRAGMIN(R) as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Apr 2007
Humate-P(R) Approved to Prevent Excessive Bleeding in Patients with von Willebrand Disease Undergoing Surgery
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Apr 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Apr 2007
Hemedex Signs Distribution Agreement with Codman
Devices Monitoring Neurosurgery Distribution

HSMN NewsFeed - 20 Apr 2007
The Lancet Publishes PREVAIL Study Results Showing Lovenox(R) Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Biopharmaceuticals

HSMN NewsFeed - 17 Apr 2007
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Apr 2007
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Apr 2007
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, PROMACTA(R), in ITP
Biopharmaceuticals

HSMN NewsFeed - 11 Apr 2007
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 5 Apr 2007
PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Apr 2007
FDA Approves Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Mar 2007
Corum Medical Signs Licensing Agreement with Brown University and Rhode Island Hospital
Devices Monitoring Licensing

HSMN NewsFeed - 26 Mar 2007
Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Mar 2007
Schering-Plough's Novel Oral Thrombin Receptor Antagonist Meets Primary Endpoint in Phase II Trial
Biopharmaceuticals Cardiology

HSMN NewsFeed - 22 Mar 2007
First Patient Enrolled in RAPID MI-ICE Study Employing InnerCool's Endovascular Temperature Modulation Therapy for Heart Attack
Devices Cardiology

HSMN NewsFeed - 7 Mar 2007
Novation Signs New Technology Agreement With ev3 Inc.
Devices Interventional Group Purchasing

HSMN NewsFeed - 22 Feb 2007
Analysis of International Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Feb 2007
Bakri Postpartum Balloon Globally Acknowledged for Treatment of Postpartum Bleeding
Devices

HSMN NewsFeed - 8 Feb 2007
ISTA Pharmaceuticals Announces Positive Preliminary Xibrom(TM) Once-daily Formulation Clinical Results From U.S. Phase III Trials
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 5 Feb 2007
Cardium and InnerCool Announce New External and Internal Patient Temperature Modulation Systems
Devices

HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and MediVas Announce Research Partnership to Develop Advanced Hemophilia Therapies
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies
Biopharmaceuticals Licensing

HSMN NewsFeed - 2 Feb 2007
Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 22 Jan 2007
Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with VELCADE(R) to Treat Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Jan 2007
HemCon Receives CE Marking for ChitoFlex Hemorrhage Control Bandage
Devices Wound Care Regulatory

HSMN NewsFeed - 29 Dec 2006
Bradley Pharmaceuticals Announces Launch of Authorized Generic of Pamine(R) (methscopolamine bromide)
Biopharmaceuticals Generics

HSMN NewsFeed - 21 Dec 2006
ISTA Pharmaceuticals Submits Investigational New Drug Application for Eye Drop Formulation of Bepotastine for the Treatment of Allergic Conjunctivitis
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 20 Dec 2006
Biopure Announces Next Steps for Navy's Proposed 'Resus' Trauma Trial of Hemopure(R)
Biopharmaceuticals

HSMN NewsFeed - 14 Dec 2006
Nonsurgical Treatment for Arteriovenous Malformations
Devices Interventional Neurology Radiology

HSMN NewsFeed - 14 Dec 2006
Dr. Bob Tepper, President of R&D, to Leave Millennium
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Dec 2006
New England Journal of Medicine Publishes Data from Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Dec 2006
VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R) Clinical Practice Guidelines for Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Dec 2006
New Study Shows Lovenox(R) (Enoxaparin Sodium Injection) Is More Effective Than Unfractionated Heparin (UFH) for Lowering the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals

HSMN NewsFeed - 12 Dec 2006
Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study
Biopharmaceuticals

HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
New Evoltra(R) Data Shows Impressive Response and Survival Rates
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
Trial Data Showed Promacta(TM) (Eltrombopag) Decreased Bleeding Episodes and Improved Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura
Biopharmaceuticals

HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Dec 2006
VELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near Complete Response Rate in Preliminary Data From Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Nov 2006
Siemens Unveils the Largest Biplane Anatomical Coverage on the Market with the AXIOM Artis dBA Twin
Devices Radiology Cardiology Neurology

HSMN NewsFeed - 20 Nov 2006
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP)
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 9 Nov 2006
Neurobiological Technologies, Inc. Comments on Recent Stroke Trial Developments
Biopharmaceuticals Neurology

HSMN NewsFeed - 8 Nov 2006
Deep Brain Stimulation Benefits Primary Dystonia Sufferers Says Study Published in New England Journal of Medicine
Devices Neurology

HSMN NewsFeed - 1 Nov 2006
MRI Analysis Could Prevent Brain Damage From Stroke, Stanford Study Finds
Devices Radiology Neurology

HSMN NewsFeed - 30 Oct 2006
Valeant Pharmaceuticals Presents End-of-Treatment Results of DIRECT Trial for Infergen at the American Association for the Study of Liver Diseases 2006 Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2006
Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD
Biopharmaceuticals

HSMN NewsFeed - 26 Oct 2006
Lipicard's Platrol(R) - First Safe, Sustained Release Antiplatelet Drug Developed Through a Novel Platform Technology
Biopharmaceuticals Cardiology

HSMN NewsFeed - 26 Oct 2006
NXY-059 Does Not Meet Efficacy Endpoints in Phase III Trial for Acute Ischemic Stroke
Biopharmaceuticals Neurology

HSMN NewsFeed - 24 Oct 2006
Cardium Reports on Positive Effects of Hypothermia Following Heart Attack and Announces Clinical Study to Be Co-Sponsored by Swedish Cardiology Center
Devices Interventional Cardiology

HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Oct 2006
NovoSeven(R) Becomes First and Only Recombinant Therapy for Treatment of Rare, Life-Threatening Bleeding Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Oct 2006
Boston Scientific Launches Clinical Trial to Study Endovascular Treatment of Brain Aneurysms
Devices Neurology Interventional

HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Oct 2006
Actelion Ltd: Detailed Analysis of CONSCIOUS-1 Presented at CNS
Biopharmaceuticals Neurosurgery

HSMN NewsFeed - 9 Oct 2006
Johnson & Johnson Wound Management Introduces Applicator Tip That Delivers Hemostat Right Where The Surgeon Needs It
Devices Surgery Wound Care

HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Oct 2006
New England Journal of Medicine Publishes Data From Lucentis Pivotal Phase III Studies in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 25 Sep 2006
OptiMedica Announces Clinical Outcomes of 1,200 Patients Treated with PASCAL Method of Photocoagulation
Devices Ophthalmology

HSMN NewsFeed - 21 Sep 2006
Dr. Michael Morgan Reports on Benefits of InnerCool's Celsius Control System in Inducing Hypothermia During Aneurysm Surgery
Devices Neurosurgery

HSMN NewsFeed - 18 Sep 2006
Somanetics Signs Contract Development and Exclusive Licensing Agreement for Several Novel Technologies
Devices Licensing

HSMN NewsFeed - 7 Sep 2006
European commission expands indication for PLAVIX® (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 7 Sep 2006
The New England Journal of Medicine Publishes the STEEPLE Study Which Demonstrated Superior Safety Profile of LOVENOX(R)(Enoxaparin Sodium Injection) Vs. Unfractionated Heparin in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention (PCI)
Biopharmaceuticals Interventional Cardiology

HSMN NewsFeed - 20 Jul 2006
OVATION Pharmaceuticals Announces First New Drug Treatment in 20 Years for Premature Infants with Patent Ductus Arteriosus
Biopharmaceuticals Cardiology

HSMN NewsFeed - 17 Jul 2006
FDA Approves Lilly's Gemzar(R) For Ovarian Cancer Treatment
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Jul 2006
ISTA Pharmaceuticals Files New Drug Application with U.S. Food and Drug Administration for T-Pred(TM), a Tobramycin and Prednisolone Acetate Combination Product
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 30 Jun 2006
FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Jun 2006
CoTherix Licenses Exclusive Rights to Develop and Commercialize Oral and Inhaled Formulations of Fasudil for the Treatment of PAH and Stable Angina in North America and Europe From Asahi Kasei Pharma
Biopharmaceuticals Licensing

HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jun 2006
HemCon, Inc. Introduces Bandage for Emergency Medicine Market
Devices

HSMN NewsFeed - 26 Jun 2006
OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib sodium injection) Maintenance Trial in Neovascular Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 2 Jun 2006
Preliminary Results from a Phase IIIb Study Showed Patients With Wet AMD Treated With Lucentis Quarterly Experienced a 16-Letter Benefit Over the Control Group at One Year
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 1 Jun 2006
Preliminary Topline Efficacy Results from Phase II Data Show Macugen(R) (pegaptanib sodium injection) Maintained or Improved Vision in over 90 Percent of Patients with Macular Edema Associated with Central Retinal Vein Occlusion (CRVO)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 30 May 2006
ISTA Pharmaceuticals Is Initiating Phase III Clinical Trials of a New Once-Daily Formulation of Xibrom(TM) for the Treatment of Ocular Pain and Inflammation Following Cataract Surgery
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 25 May 2006
Genentech Submits Supplemental Biologics License Application for Avastin With Chemotherapy in First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 May 2006
Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients with Recurrent Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2006
Recruitment Planned to Resume in AVANT International Phase III Trial in Adjuvant Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 May 2006
Maxygen Achieves Milestone in Alliance with Roche for Factor VIIa Therapeutics
Biopharmaceuticals

HSMN NewsFeed - 4 May 2006
OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 4 May 2006
ISTA Pharmaceuticals(R) Announces Study Indicating Twice-Daily Dosing of Xibrom(TM) as Equivalent to Four Times a Day of Other Treatments
Biopharmaceuticals Ophthalmology

Return to NewsFeed

Additional items found! 266

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 266 additional stories matching:
Hemorrhage
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!